CUX1 (Homeobox protein cut-like 1) variants and mutations
CUX1 (also known as Homeobox protein cut-like 1) is a human protein-coding gene encoding a homeobox protein cut-like 1 protein. It regulates transcription and chromatin-associated processes involved in cell differentiation, proliferation, and neuronal development. Haploinsufficiency can cause neurodevelopmental impairment, while somatic loss is common in myeloid malignancies and often marks adverse-risk disease. This analysis covers 2,015 CUX1 variants and mutations. Of these, 74% have computational variant effect predictions. Disease context includes global developmental delay with or without impaired intellectual development, cancer, and myelodysplastic syndrome. Example CUX1 variants include M1V, M1L, and M1R.
Variant analysis overview
- Gene: CUX1
- Protein: Homeobox protein cut-like 1
- UniProt accession: P39880
- Organism: Homo sapiens
- Variants analyzed: 2015
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 1,921 unspecified-consequence records; 66 missense variants; 6 frameshift variants; 15 synonymous variants; 4 stop-gained variants; 1 in-frame insertions; 2 substitution
- Prediction scores: 1,500 variants have prediction scores (74% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: global developmental delay with or without impaired intellectual development, cancer, myelodysplastic syndrome, hereditary disease, acute lymphoblastic leukemia, leukemia, breast carcinoma, atrial fibrillation, neurodevelopmental disorder, chronic myelogenous leukemia, BCR-ABL1 positive, preeclampsia, alcohol drinking.
Protein structure and variant hotspots
- Protein features: 10 post-translational modification sites.
- PTM context: 10 variants overlap post-translational modification sites.
- Experimental data: 82 protein positions have experimental scores. Source: CUX1 Homeobox domain domainome 1.0, CUX1 CUT domain domainome 1.0.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CUX1 variants
Examples include M1V, M1L, M1R, M1T, M1K, M1I, L2*, L2S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs1791725485, gnomAD 7-101816052-A-G, CADD 21.30, SIFT 0.14
- M1L (p.Met1Leu), gnomAD 7-101816052-A-C, CADD 18.30, SIFT 0.05
- M1R (p.Met1Arg), rs2130846903, gnomAD 7-101816053-T-G, CADD 23.40, SIFT 0.00
- M1T (p.Met1Thr), gnomAD 7-101816053-T-C, CADD 23.00, SIFT 0.00
- M1K (p.Met1Lys), gnomAD 7-101816053-T-A, CADD 23.30, SIFT 0.00
- M1I (p.Met1Ile), gnomAD 7-101816054-G-A, CADD 23.40, SIFT 0.01
- L2* (p.Leu2Ter), gnomAD rs1477929719, CADD 21.70
- L2S (p.Leu2Ser), gnomAD rs1477929719, REVEL 0.15, MetaLR 0.11
- L2F (p.Leu2Phe), gnomAD 7-101817645-G-T, REVEL 0.10, MetaLR 0.09
- L2L (p.Leu2Leu), gnomAD 7-101817645-G-A, CADD 20.30
- C3* (p.Cys3Ter), 1000Genomes rs542931508, TOPMed rs542931508, gnomAD rs542931508, CADD 15.70
- C3G (p.Cys3Gly), gnomAD 7-101817646-T-G, REVEL 0.27, MetaLR 0.17
- C3S (p.Cys3Ser), gnomAD 7-101817646-T-A, REVEL 0.28, MetaLR 0.16
- C3Y (p.Cys3Tyr), gnomAD 7-101817647-G-A, REVEL 0.22, MetaLR 0.19
- C3F (p.Cys3Phe), gnomAD 7-101817647-G-T, REVEL 0.23, MetaLR 0.19
- C3W (p.Cys3Trp), gnomAD 7-101817648-C-G, REVEL 0.24, MetaLR 0.16
- C3C (p.Cys3Cys), rs542931508, gnomAD 7-101817648-C-T, CADD 16.10
- V4I (p.Val4Ile), gnomAD rs1420874680, REVEL 0.04, MetaLR 0.09
- V4L (p.Val4Leu), gnomAD 7-101816043-G-T, CADD 21.10, SIFT 0.28
- V4M (p.Val4Met), gnomAD 7-101816043-G-A, CADD 22.30, SIFT 0.02
- V4A (p.Val4Ala), rs748916298, gnomAD 7-101816044-T-C, CADD 19.30, SIFT 1.00
- V4G (p.Val4Gly), gnomAD 7-101816044-T-G, CADD 23.80, SIFT 0.05
- V4V (p.Val4Val), gnomAD 7-101816045-G-T, CADD 12.40
- V4E (p.Val4Glu), gnomAD 7-101817650-T-A, REVEL 0.27, MetaLR 0.12
- A5V (p.Ala5Val), TOPMed rs1792016659, REVEL 0.13, MetaLR 0.08
- A5T (p.Ala5Thr), gnomAD 7-101816034-G-A, CADD 23.60, SIFT 0.00
- A5G (p.Ala5Gly), gnomAD 7-101816034-GC-G, CADD 28.00
- A5S (p.Ala5Ser), gnomAD 7-101816034-G-T, CADD 23.20, SIFT 0.00
- A5E (p.Ala5Glu), gnomAD 7-101816035-C-A, CADD 24.20, SIFT 0.00
- A5A (p.Ala5Ala), rs1791722272, gnomAD 7-101816036-G-A, CADD 14.70
- A5D (p.Ala5Asp), gnomAD 7-101816038-C-A, CADD 23.30, SIFT 0.00
- G6D (p.Gly6Asp), gnomAD 7-101816044-TG-T, CADD 25.50
- G6R (p.Gly6Arg), rs1164370058, gnomAD 7-101816046-G-A, CADD 24.00, SIFT 0.00
- G6* (p.Gly6Ter), gnomAD 7-101816046-G-T, CADD 35.00
- G6E (p.Gly6Glu), gnomAD 7-101816047-G-A, CADD 22.60, SIFT 0.00
- G6V (p.Gly6Val), gnomAD 7-101816047-G-T, CADD 20.70, SIFT 0.04
- G6A (p.Gly6Ala), rs1351266529, gnomAD 7-101816047-G-C, CADD 17.60, SIFT 0.16
- G6G (p.Gly6Gly), gnomAD 7-101816048-A-T, CADD 15.70
- A7P (p.Ala7Pro), gnomAD 7-101817657-AG-A, CADD 17.80
- A7S (p.Ala7Ser), gnomAD 7-101817658-G-T, REVEL 0.06, MetaLR 0.03
- A7T (p.Ala7Thr), gnomAD 7-101817658-G-A, REVEL 0.07, MetaLR 0.03
- A7D (p.Ala7Asp), gnomAD 7-101817659-C-A, REVEL 0.03, MetaLR 0.03
- A7V (p.Ala7Val), gnomAD 7-101817659-C-T, REVEL 0.04, MetaLR 0.03
- A7A (p.Ala7Ala), gnomAD 7-101817660-C-T, CADD 18.30
- R8G (p.Arg8Gly), TOPMed rs1173103796, gnomAD rs1173103796, REVEL 0.10, MetaLR 0.04
- R8K (p.Arg8Lys), TOPMed rs1401326458, gnomAD rs1401326458, REVEL 0.06, MetaLR 0.02
- R8W (p.Arg8Trp), gnomAD 7-101817661-A-T, REVEL 0.06, MetaLR 0.05
- R8S (p.Arg8Ser), gnomAD 7-101817661-AG-A, CADD 17.50
- R8M (p.Arg8Met), gnomAD 7-101817662-G-T, REVEL 0.06, MetaLR 0.04
- R8T (p.Arg8Thr), gnomAD 7-101817662-G-C, REVEL 0.09, MetaLR 0.03
- L9V (p.Leu9Val), gnomAD 7-101817664-T-G, REVEL 0.06, MetaLR 0.05
- L9M (p.Leu9Met), gnomAD 7-101817664-T-A, REVEL 0.08, MetaLR 0.07
- L9S (p.Leu9Ser), gnomAD 7-101817665-T-C, REVEL 0.11, MetaLR 0.08
- L9F (p.Leu9Phe), gnomAD 7-101817666-G-T, REVEL 0.11, MetaLR 0.07
- L9L (p.Leu9Leu), gnomAD 7-101817666-G-A, CADD 18.50
- K10R (p.Lys10Arg), TOPMed rs1394140833, gnomAD rs1394140833, REVEL 0.05, MetaLR 0.04
- K10S (p.Lys10Ser), gnomAD 7-101816066-GA-G, CADD 25.10
- K10* (p.Lys10Ter), gnomAD 7-101816067-A-T, CADD 37.00
- K10E (p.Lys10Glu), gnomAD 7-101816067-A-G, CADD 23.00, SIFT 0.05
- K10M (p.Lys10Met), gnomAD 7-101816068-A-T, CADD 22.80, SIFT 0.01
- K10K (p.Lys10Lys), gnomAD 7-101816069-G-A, CADD 13.60
- K10N (p.Lys10Asn), gnomAD 7-101816069-G-T, CADD 25.00, SIFT 0.00
- R11G (p.Arg11Gly), TOPMed rs1177297232, gnomAD rs1177297232, REVEL 0.34, MetaLR 0.05
- R11S (p.Arg11Ser), ESP rs140709702, REVEL 0.23, MetaLR 0.04
- R11T (p.Arg11Thr), gnomAD rs1804168189, REVEL 0.24, MetaLR 0.05
- R11C (p.Arg11Cys), gnomAD 7-101816070-C-T, CADD 23.00, SIFT 0.00
- R11H (p.Arg11His), rs775827401, gnomAD 7-101816071-G-A, CADD 23.00, SIFT 0.09
- R11L (p.Arg11Leu), rs775827401, gnomAD 7-101816071-G-T, CADD 22.90, SIFT 0.01
- R11P (p.Arg11Pro), gnomAD 7-101816071-G-C, CADD 26.10, SIFT 0.00
- R11R (p.Arg11Arg), gnomAD 7-101816072-C-A, CADD 14.10
- R11I (p.Arg11Ile), gnomAD 7-101916116-G-T, REVEL 0.27, MetaLR 0.06
- E12* (p.Glu12Ter), NCI-TCGA Cosmic COSV9947, cosmic curated COSV99472, CADD 37.00, Variant assessed as somatic; high impact.
- E12G (p.Glu12Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E12K (p.Glu12Lys), cosmic curated COSV10587, MetaLR 0.12, MetaSVM -1.01
- D14N (p.Asp14Asn), ExAC rs756778760, gnomAD rs756778760, REVEL 0.12, MetaLR 0.25
- D14V (p.Asp14Val), NCI-TCGA Cosmic COSV5291, cosmic curated COSV52918, MetaLR 0.36, MetaSVM -0.30, Variant assessed as somatic; moderate impact.
- D14H (p.Asp14His), gnomAD 7-101816076-G-C, CADD 27.40, SIFT 0.00
- D14Y (p.Asp14Tyr), gnomAD 7-101816076-G-T, CADD 24.80, SIFT 0.00
- D14G (p.Asp14Gly), gnomAD 7-101816077-A-G, CADD 26.70, SIFT 0.01
- D14D (p.Asp14Asp), gnomAD 7-101816078-T-C, CADD 14.80
- A15D (p.Ala15Asp), NCI-TCGA Cosmic COSV5290, NCI-TCGA Cosmic COSV9947, cosmic curated COSV99471, ExAC rs778368760, REVEL 0.22, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- A15G (p.Ala15Gly), ExAC rs778368760, TOPMed rs778368760, gnomAD rs778368760, REVEL 0.07, MetaLR 0.10
- A15T (p.Ala15Thr), cosmic curated COSV52902, gnomAD rs1804169491, REVEL 0.03, MetaLR 0.05
- A15V (p.Ala15Val), NCI-TCGA Cosmic COSV5290, cosmic curated COSV52904, NCI-TCGA Cosmic COSV9947, REVEL 0.15, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- T16A (p.Thr16Ala), Ensembl rs1804170258, REVEL 0.19, MetaLR 0.16
- T16S (p.Thr16Ser), cosmic curated COSV52895, MetaLR 0.17, MetaSVM -0.87
- A17T (p.Ala17Thr), rs867880450, NCI-TCGA Cosmic COSV5290, cosmic curated COSV52908, gnomAD rs867880450, REVEL 0.28, MetaLR 0.22, Variant assessed as somatic; moderate impact.
- T18A (p.Thr18Ala), rs1376583186, NCI-TCGA Cosmic COSV9947, cosmic curated COSV99471, gnomAD rs1376583186, AlphaMissense 0.27, MetaLR 0.11, Variant assessed as somatic; moderate impact.
- T18M (p.Thr18Met), rs1804171761, ClinGen CA368909475, cosmic curated COSV99473, ClinVar RCV002265069, REVEL 0.25, MetaLR 0.16, Uncertain significance, not provided
- T18S (p.Thr18Ser), gnomAD rs1376583186, REVEL 0.12, AlphaMissense 0.27, Likely benign, Global developmental delay with or without impaired intellectual development
- V19I (p.Val19Ile), Ensembl rs1804172410, MetaLR 0.05, MetaSVM -1.10
- p.Leu17 Gln18insHisTrpLysArgPheA, gnomAD 7-101816061-T-TAT, CADD 18.40
- L20Y (p.Leu20Tyr), gnomAD 7-101816077-AT-A, CADD 26.30
- L20L (p.Leu20Leu), gnomAD 7-101816079-T-C, CADD 14.90
- L20I (p.Leu20Ile), rs1791727410, gnomAD 7-101816079-T-A, CADD 22.40, SIFT 0.01
- L20S (p.Leu20Ser), gnomAD 7-101816080-T-C, CADD 26.70, SIFT 0.00
- L20F (p.Leu20Phe), gnomAD 7-101816081-A-T, CADD 22.20, SIFT 0.03
- L20V (p.Leu20Val), gnomAD 7-101816088-C-G, CADD 24.00, SIFT 0.05
- L20M (p.Leu20Met), gnomAD 7-101816088-C-A, CADD 25.30, SIFT 0.03
- L20P (p.Leu20Pro), gnomAD 7-101816089-T-C, CADD 27.40, SIFT 0.11
- A21T (p.Ala21Thr), NCI-TCGA Cosmic COSV5289, cosmic curated COSV52898, MetaLR 0.15, MetaSVM -0.97, Variant assessed as somatic; moderate impact.
- A21V (p.Ala21Val), cosmic curated COSV52904, ExAC rs779702615, TOPMed rs779702615, gnomAD rs779702615, REVEL 0.24, MetaLR 0.14
- N22K (p.Asn22Lys), cosmic curated COSV99035, REVEL 0.12, MetaLR 0.11
- N22H (p.Asn22His), rs2130846733, gnomAD 7-101816040-A-C, CADD 23.20, SIFT 0.00
- N22D (p.Asn22Asp), gnomAD 7-101816040-A-G, CADD 20.90, SIFT 0.00
- N22T (p.Asn22Thr), gnomAD 7-101816041-A-C, CADD 23.40, SIFT 0.02
- N22S (p.Asn22Ser), rs772940813, gnomAD 7-101816041-A-G, CADD 21.80, SIFT 0.17
- N22N (p.Asn22Asn), rs1224246553, gnomAD 7-101816042-T-C, CADD 14.30
- R23Q (p.Arg23Gln), gnomAD rs1280730199, REVEL 0.31, MetaLR 0.17, Uncertain significance, Global developmental delay with or without impaired intellectual development
- R23W (p.Arg23Trp), TOPMed rs1804173953, REVEL 0.30, MetaLR 0.18
- Q24K (p.Gln24Lys), gnomAD 7-101816058-C-A, CADD 22.20, SIFT 0.02
- Q24E (p.Gln24Glu), gnomAD 7-101816058-C-G, CADD 22.40, SIFT 0.03
- Q24* (p.Gln24Ter), gnomAD 7-101816058-C-T, CADD 36.00
- Q24P (p.Gln24Pro), gnomAD 7-101816059-A-C, CADD 24.60, SIFT 0.06
- Q24R (p.Gln24Arg), gnomAD 7-101816059-A-G, CADD 21.90, SIFT 0.08
- Q24Q (p.Gln24Gln), rs1030454885, gnomAD 7-101816060-A-G, CADD 13.80
- Q24H (p.Gln24His), gnomAD 7-101816084-G-T, CADD 21.00, SIFT 0.00
- D25E (p.Asp25Glu), ExAC rs778447580, gnomAD rs778447580, REVEL 0.11, MetaLR 0.12, Uncertain significance, Inborn genetic diseases
- S27N (p.Ser27Asn), cosmic curated COSV10587, REVEL 0.17, MetaLR 0.20
- S27P (p.Ser27Pro), gnomAD 7-101816049-T-C, CADD 23.50, SIFT 0.00
- S27* (p.Ser27Ter), gnomAD 7-101816050-C-A, CADD 36.00
- S27L (p.Ser27Leu), rs1791724951, gnomAD 7-101816050-C-T, CADD 23.70, SIFT 0.05
- S27S (p.Ser27Ser), gnomAD 7-101816051-G-T, CADD 14.80
- E28V (p.Glu28Val), NCI-TCGA Cosmic COSV9947, cosmic curated COSV99472, MetaLR 0.17, MetaSVM -0.76, Variant assessed as somatic; moderate impact.
- S30F (p.Ser30Phe), cosmic curated COSV52893
- R31* (p.Arg31Ter), cosmic curated COSV10963
- R31I (p.Arg31Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R33Q (p.Arg33Gln), cosmic curated COSV52891, ExAC rs200309302, TOPMed rs200309302, gnomAD rs200309302, REVEL 0.10, MetaLR 0.06
- R33W (p.Arg33Trp), rs771176824, ClinGen CA163802516, cosmic curated COSV52900, ClinVar RCV002282848, REVEL 0.23, MetaLR 0.20, Uncertain significance, not specified
- E36D (p.Glu36Asp), cosmic curated COSV10587, MetaLR 0.15, MetaSVM -0.97
- E36K (p.Glu36Lys), rs1404930496, NCI-TCGA Cosmic COSV5289, cosmic curated COSV52894, TOPMed rs1404930496, REVEL 0.30, MetaLR 0.34, Variant assessed as somatic; moderate impact.
- Q37* (p.Gln37Ter), ExAC rs772195790, gnomAD rs772195790, CADD 36.00
- R39W (p.Arg39Trp), TOPMed rs1201682206, gnomAD rs1201682206, REVEL 0.28, MetaLR 0.25
- F41L (p.Phe41Leu), cosmic curated COSV10880, Uncertain significance, not provided
- F41V (p.Phe41Val), Ensembl rs1584970734, MetaLR 0.26, MetaSVM -0.58
- F41S (p.Phe41Ser), gnomAD 7-101816056-T-C, CADD 24.10, SIFT 0.04
- F41F (p.Phe41Phe), gnomAD 7-101816057-T-C, CADD 15.00
- F41I (p.Phe41Ile), gnomAD 7-101816073-T-A, CADD 22.50, SIFT 0.01
- K43N (p.Lys43Asn), rs748511869, ClinGen CA4410342, ClinVar RCV003308895, ExAC rs748511869, REVEL 0.21, MetaLR 0.22, Uncertain significance, Inborn genetic diseases
- K43R (p.Lys43Arg), Ensembl rs1804179732, MetaLR 0.24, MetaSVM -0.61
- N44S (p.Asn44Ser), cosmic curated COSV52892, ExAC rs760414074, gnomAD rs760414074, REVEL 0.06, MetaLR 0.07
- N44T (p.Asn44Thr), ExAC rs760414074, gnomAD rs760414074, MetaLR 0.08, MetaSVM -1.07
- N44Y (p.Asn44Tyr), TOPMed rs1305374736, gnomAD rs1305374736, REVEL 0.32, MetaLR 0.19
- T45I (p.Thr45Ile), ESP rs149191757, ExAC rs149191757, TOPMed rs149191757, gnomAD rs149191757, REVEL 0.24, MetaLR 0.20
- P46L (p.Pro46Leu), ExAC rs761704472, gnomAD rs761704472, REVEL 0.28, MetaLR 0.20
- P46Q (p.Pro46Gln), cosmic curated COSV52893
- P46S (p.Pro46Ser), cosmic curated COSV52919, MetaLR 0.19, MetaSVM -0.84
- E47* (p.Glu47Ter), NCI-TCGA Cosmic COSV9947, cosmic curated COSV99471, Variant assessed as somatic; high impact.
- L49V (p.Leu49Val), cosmic curated COSV52915, MetaLR 0.15, MetaSVM -0.87
- R50C (p.Arg50Cys), NCI-TCGA TCGA novel, REVEL 0.36, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- R50H (p.Arg50His), NCI-TCGA TCGA novel, gnomAD rs1820255949, REVEL 0.31, MetaLR 0.20, Variant assessed as somatic; moderate impact.
- K51E (p.Lys51Glu), TOPMed rs1820256270, MetaLR 0.14, MetaSVM -1.03
- K51N (p.Lys51Asn), TOPMed rs1253387040, gnomAD rs1253387040, REVEL 0.09, MetaLR 0.12
- Q52P (p.Gln52Pro), Ensembl rs2129333061, REVEL 0.18, MetaLR 0.09
- A54G (p.Ala54Gly), rs143267032, ClinGen CA4410374, NCI-TCGA Cosmic COSV5289, ClinVar RCV004375326, REVEL 0.19, MetaLR 0.16, Uncertain significance, Inborn genetic diseases
- A54S (p.Ala54Ser), Ensembl rs1820256949, MetaLR 0.15, MetaSVM -1.06
- A54V (p.Ala54Val), NCI-TCGA Cosmic COSV5289, cosmic curated COSV52897, REVEL 0.16, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- P55L (p.Pro55Leu), rs1213438024, NCI-TCGA Cosmic COSV9947, cosmic curated COSV99473, gnomAD rs1213438024, REVEL 0.26, MetaLR 0.24, Uncertain significance, not provided
- L57M (p.Leu57Met), TOPMed rs1820261122, Uncertain significance, Inborn genetic diseases
- L57P (p.Leu57Pro), cosmic curated COSV52894, MetaLR 0.27, MetaSVM -0.51
- S59G (p.Ser59Gly), TOPMed rs989872151, gnomAD rs989872151, REVEL 0.23, MetaLR 0.17
- F60S (p.Phe60Ser), NCI-TCGA TCGA novel, MetaLR 0.28, MetaSVM -0.50, Variant assessed as somatic; moderate impact.
- Q61* (p.Gln61Ter), cosmic curated COSV52900
- Q61H (p.Gln61His), cosmic curated COSV52918, MetaLR 0.26, MetaSVM -0.46
- E63* (p.Glu63Ter), cosmic curated COSV10511
- E63K (p.Glu63Lys), cosmic curated COSV10642, MetaLR 0.31, MetaSVM -0.49
- I64T (p.Ile64Thr), gnomAD rs1173048193, REVEL 0.47, MetaLR 0.25
- A66V (p.Ala66Val), cosmic curated COSV10963, REVEL 0.29, MetaLR 0.31
- S68R (p.Ser68Arg), NCI-TCGA TCGA novel, MetaLR 0.18, MetaSVM -0.80, Variant assessed as somatic; moderate impact.
- S71R (p.Ser71Arg), cosmic curated COSV10963, REVEL 0.30, MetaLR 0.29
- E73K (p.Glu73Lys), cosmic curated COSV52902, MetaLR 0.50, MetaSVM -0.07
- A74V (p.Ala74Val), cosmic curated COSV52920
- E75* (p.Glu75Ter), cosmic curated COSV10642
- E75G (p.Glu75Gly), gnomAD rs1361406242, REVEL 0.58, MetaLR 0.72
- E75V (p.Glu75Val), NCI-TCGA TCGA novel, MetaLR 0.72, MetaSVM 0.57, Variant assessed as somatic; moderate impact.
- A76T (p.Ala76Thr), cosmic curated COSV52920, MetaLR 0.10, MetaSVM -1.06
- F78L (p.Phe78Leu), NCI-TCGA TCGA novel, MetaLR 0.22, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- N80D (p.Asn80Asp), Ensembl rs1825993360, MetaLR 0.09, MetaSVM -1.07
- N80K (p.Asn80Lys), gnomAD rs1397038203, REVEL 0.07, MetaLR 0.10, Uncertain significance, not provided
- Y82C (p.Tyr82Cys), TOPMed rs915704529, gnomAD rs915704529, REVEL 0.65, MetaLR 0.24, Uncertain significance, Inborn genetic diseases
Public CUX1 analysis runs
- CUX1 analysis run — CUX1 (2,015 variants) — completed 2026-08-20